Literature DB >> 32476958

A prospective study of patients diagnosed with sarcoidosis: factors - environmental exposure, health assessment, and genetic outlooks.

Louis B Caruana1, Gerald D Redwine1, Rodney E Rohde1, Chris J Russian2.   

Abstract

This original research is a directional study that determined the habits of individuals using four analyses to find statistical significance in the data collected from the surveys of 801 qualified of 1,340 individuals who agreed to participate. Results from the self-reported diagnosis of individuals affected by sarcoidosis produced seven statistically significant indicators of future research needed. The demographics revealed a significantly greater number of women and African-Americans participants than other minorities in the United States and suggested a sense of urgency to find a cure. Most important are the seven statistically significant findings that also gave credence to the researchers' four subdiagnostic classifications. They are acute sarcoidosis (AS) and chronic sarcoidosis with limited dissemination (CSLD), while more severe cases include those with chronic sarcoidosis with full dissemination including cutaneous involvement (CSFDIC) and chronic sarcoidosis with neurosarcoidosis (CSN). The most severe sarcoidosis cases (CSN) were on the "most likely" side of every statistically significant category except drinking alcohol, and the "least likely" to participate in physical activities. Conversely, the least severe case of sarcoidosis (AS) was the opposite. The complete list of statistically significant areas was related to alcohol use, tobacco use, ciprofloxacin use, environmental exposure to metals (copper, iron), infectious diseases (candidiasis), genetics, and physical exercise. Statistically, the most crucial study needed; emerged from the Rh blood grouping of the participants. Copyright:
© 2020.

Entities:  

Keywords:  environmental exposure; genetics; sarcoidosis

Mesh:

Substances:

Year:  2019        PMID: 32476958      PMCID: PMC7247080          DOI: 10.36141/svdld.v36i3.7112

Source DB:  PubMed          Journal:  Sarcoidosis Vasc Diffuse Lung Dis        ISSN: 1124-0490            Impact factor:   0.670


  18 in total

1.  Occupational risk factors for sarcoidosis in African-American siblings.

Authors:  Gena P Kucera; Benjamin A Rybicki; Kandace L Kirkey; Steven W Coon; Marcie L Major; Mary J Maliarik; Michael C Iannuzzi
Journal:  Chest       Date:  2003-05       Impact factor: 9.410

2.  Potential usefulness of a combination of inflammatory markers in identifying patients with sarcoidosis and monitoring respiratory functional worsening.

Authors:  Gregorino Paone; Ilio Cammarella; Gian Luca Di Tanna; Annarita Vestri; Alvaro Leone; Sandro Batzella; Francesco Belli; Giovanni Galluccio; Alfredo Sebastiani; Vittoria Conti; Claudio Terzano
Journal:  Am J Clin Pathol       Date:  2012-03       Impact factor: 2.493

3.  Sarcoidosis in black women in the United States: data from the Black Women's Health Study.

Authors:  Yvette C Cozier; Jeffrey S Berman; Julie R Palmer; Deborah A Boggs; David M Serlin; Lynn Rosenberg
Journal:  Chest       Date:  2010-07-01       Impact factor: 9.410

4.  Löfgren syndrome in acute sarcoidosis.

Authors:  Alexandra P Saltman; Bindee Kuriya
Journal:  CMAJ       Date:  2017-10-02       Impact factor: 8.262

5.  A simple method to assess exercise behavior in the community.

Authors:  G Godin; R J Shephard
Journal:  Can J Appl Sport Sci       Date:  1985-09

6.  Ciprofloxacin-induced acute interstitial pneumonitis.

Authors:  D Steiger; L Bubendorf; M Oberholzer; M Tamm; J D Leuppi
Journal:  Eur Respir J       Date:  2004-01       Impact factor: 16.671

7.  Sarcoidosis in America. Analysis Based on Health Care Use.

Authors:  Robert P Baughman; Shelli Field; Ulrich Costabel; Ronald G Crystal; Daniel A Culver; Marjolein Drent; Marc A Judson; Gerhard Wolff
Journal:  Ann Am Thorac Soc       Date:  2016-08

8.  Sarcoidosis and mechanisms of unexpected death.

Authors:  Roger W Byard; Nicholas Manton; Michael Tsokos
Journal:  J Forensic Sci       Date:  2008-03       Impact factor: 1.832

9.  Sinonasal sarcoidosis: A new system of classification acting as a guide to diagnosis and treatment.

Authors:  William Lawson; Nancy Jiang; Jeffrey Cheng
Journal:  Am J Rhinol Allergy       Date:  2014 Jul-Aug       Impact factor: 2.467

Review 10.  Efficacy and adverse effects of medical marijuana for chronic noncancer pain: Systematic review of randomized controlled trials.

Authors:  Amol Deshpande; Angela Mailis-Gagnon; Nivan Zoheiry; Shehnaz Fatima Lakha
Journal:  Can Fam Physician       Date:  2015-08       Impact factor: 3.275

View more
  5 in total

1.  Macrophage Migration Inhibitory Factor is not Associated with Sarcoidosis Susceptibility or Severity in Whites or Blacks.

Authors:  Camila D Odio; Eward J Miller; Maor Sauler; Lin Leng; Marta Piecychna; Wonder P Drake; Richard Bucala
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2020-09-30       Impact factor: 0.670

2.  Investigation of sarcoidosis patients during COVID-19 pandemic.

Authors:  Arda Kiani; Fatemeh Razavi; Negar Bandegani; Mehrdad Farahani; Atefeh Abedini
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2020-12-16       Impact factor: 0.670

Review 3.  Hypothalamic-Pituitary Axis Dysfunction, Central Diabetes Insipidus, and Syndrome of Inappropriate Antidiuretic Hormone Secretion as the First Clinical Presentation of Neurosarcoidosis: Why Early Diagnosis and Treatment is Important?

Authors:  Tatjana Blazin; Dhruvil Prajapati; Linha Lina M Mohammed; Meera Dhavale; Mohamed K Abdelaal; A B M Nasibul Alam; Natalia P Ballestas; Jihan A Mostafa
Journal:  Cureus       Date:  2020-11-14

4.  Sarcoidosis: a prospective observational cohort from Northern Alberta.

Authors:  Dilini Vethanayagam; Jillian Peters; Emad Saad; Kimberley Mulchey; Ashley-Mae Gillson; Brian McNab; Maxine Farr-Jones; Tomasz Hruczkowski; Gregg Blevins; Richard Coulden; Gavin Oudit; Jeremy Beach
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2020-12-16       Impact factor: 0.670

5.  Cost drivers in the pharmacological treatment of interstitial lung disease.

Authors:  Phillen Nozibuyiso Maqhuzu; Michael Kreuter; Thomas Bahmer; Nicolas Kahn; Martin Claussen; Rolf Holle; Larissa Schwarzkopf
Journal:  Respir Res       Date:  2021-08-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.